Despite these differences at the gene level, both PTs and adenosarcomas appear to have enrichment for somatic genetic alterations affecting genes pertaining to four main pathways: p53/MDM2, pRb/CDK4, PI3K, and Wnt/β‐catenin signaling pathways. The gene discussed is MDM2; the disease is adenosarcoma.